Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Seelos Therapeutics Inc (SEEL)

Seelos Therapeutics Inc (SEEL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,869
  • Shares Outstanding, K 22,475
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,240 K
  • 60-Month Beta 0.79
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.12
  • Number of Estimates 2
  • High Estimate -0.12
  • Low Estimate -0.12
  • Prior Year -3.60
  • Growth Rate Est. (year over year) +96.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.16 +6.90%
on 09/06/19
1.98 -37.37%
on 08/22/19
-0.43 (-25.75%)
since 08/13/19
3-Month
1.16 +6.90%
on 09/06/19
2.54 -51.18%
on 06/27/19
-1.09 (-46.78%)
since 06/13/19
52-Week
1.16 +6.90%
on 09/06/19
12.90 -90.39%
on 10/17/18
-7.31 (-85.50%)
since 09/13/18

Most Recent Stories

More News
Cancer Biology Clinical Research Seeking Answers at Cellular Level

Research for the cure for cancer has become this generation's version of President John F. Kennedy's May 25, 1961 proclamation to "Landing a man on the Moon and returning him safely". Much money and effort...

CPRX : 6.21 (+1.31%)
CCXI : 7.58 (-0.79%)
MBRX : 1.22 (+3.39%)
SEEL : 1.24 (+1.64%)
BMY : 49.43 (-0.36%)
Accelerated Clinical Trials Bridging Gateway to Latest Treatments for Cancer Patients

Cancer research has for years been steadily gaining ground on its way to managing, curing and even preventing the various forms of this insidious disease. Both public and private money continues to flow...

ELAN : 28.68 (+1.06%)
AKBA : 5.10 (-3.04%)
PFE : 36.91 (-0.99%)
MBRX : 1.22 (+3.39%)
SEEL : 1.24 (+1.64%)
FDA Regulations Allow Medical Devices Clinical Trials to Differ From Pharmaceutical Trials

Clinical trials are the pathway for new drugs or devices to enter the U.S. and other worldwide markets. However, not all clinical trials are the same. A recent article by a 20+ year insider in the clinical...

ARQL : 7.97 (+0.89%)
LLY : 110.89 (-0.52%)
BPTH : 11.88 (+5.04%)
SOLY : 13.26 (+1.30%)
SEEL : 1.24 (+1.64%)
Seelos Therapeutics Completes Acquisition of Trehalose from Bioblast Pharma

Diversifies Seelos' pipeline in rare diseases

ORPN : 11.50 (+6.68%)
SEEL : 1.24 (+1.64%)
Bioblast Pharma Announces Sale of its Trehalose Clinical Development Programs to Seelos Therapeutics

-- Unconditional payment of $3.5 million

ORPN : 11.50 (+6.68%)
SEEL : 1.24 (+1.64%)
Seelos Therapeutics, Inc. Announces Successful Completion of its Merger with Apricus Biosciences, Inc. to Advance Late-Stage Pipeline of Products for Central Nervous System (CNS) Disorders

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients...

LGND : 97.44 (-0.11%)
APRI : 0.22 (-4.35%)
SEEL : 1.24 (+1.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade SEEL with:

Business Summary

Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which...

See More

Key Turning Points

2nd Resistance Point 1.28
1st Resistance Point 1.26
Last Price 1.24
1st Support Level 1.22
2nd Support Level 1.20

See More

52-Week High 12.90
Fibonacci 61.8% 8.42
Fibonacci 50% 7.03
Fibonacci 38.2% 5.64
Last Price 1.24
52-Week Low 1.16

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar